check out one month chart- im a buyer
Patients Alive After 24 Months- 31.1% On Vyxeos Compared to Only 12.3% On 7+3 am LINK
Celator Pharma Skyrockets on Breakthrough Trial Results
The percentage of patients alive 12 months after randomization was 41.5% on the Vyxeos arm, compared to27.6% on the 7+3 arm. The percentage of patients alive 24 months after randomization was 31.1% on the Vyxeos arm, compared to 12.3% on the 7+3 arm.
This would be huge !!!!!!!!
Sentiment: Strong Buy
Summit Research Says CyberArk's Cutting Edge Technology Is Appealing To Many Businesses, Says Cisco And IBM Would Also Have Use For CyberArk Assets, Expects Consolidation In Sector And Believes CyberArk Could Go For A PremiumEddie Staley , Benzinga Staff Writer
Just the Beginning- Big Pipeline
ZIOPHARM Announces Orphan Drug Designation for Ad-RTS-hIL-12 in the Treatment of Malinant
Ocera Therapeutics Rises on Positive Results
24/7 Wall St. By Chris Lange
For some background: OCR-002 is an ammonia scavenger and has been granted orphan drug designation
and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease
Chimerix(NASDAQ: CMRX) “remains committed to better understanding the full data set as we consider potential paths forward for brincidofovir.” Currently Chimerix has a strong cash position and leadership team
wow, grabbed some.
Word on the street is they will beat earnings
Sanofi In Talks To Buy PTC Therapeutics ( PTCT )
Paris-based Sanofi SA (ADR)
has restarted negotiations to acquire New Jersey's PTC Therapeutics, Inc.
Société Générale is said to be working on the deal.
Both sides began talks earlier this week after PTC said it received a Refuse to File notice from the FDA regarding its Translarna treatment. The disclosure, which pushed shares down more than 50 percent, was the result of an error and has no material bearing on PTC or Translarna's fundamental outlook, according to the source.